3 results about "Malaria vaccine" patented technology

Systems, compositions, devices, methods, etc., provide improved anti-malaria immunological responses comprising making, providing and administering vaccines comprising specific RNA molecules such as self-replicating replicon RNA (repRNA) encoding proteins from Plasmodium such as the P. yoelii (Py) CS protein (CSP), including in some embodiments substantially target proteins encoding target antigens, for example a whole or substantially whole CSP in the repRNA. The prime-and-trap intervals for the administration of the vaccine can comprise administration of only a single dose of a repRNA-Non-encapsulating oil-in-water emulsion nanocarriers (e.g., LION™) component followed by administration of as few as 3 or 2 doses, or even just a single dose, of the WO component (e.g., RAS or genetically attenuated WO) at 0 day (same day), or 1, 2, 3, 4, 5, 10, 14, 15 days or 28 days later.

The application belongs to the field of genetic engineering, and discloses a recombinant protein and application thereof in malaria transmission blocking. In the present application, geap36 is coupled with AP205 by using SpyTag-SpyCatcher reaction. The technology is novel at present, and is different from traditional malaria vaccines which only use proteins expressed in a certain stage of Plasmodium as immunogens. Due to the addition of AP205 protein, the AP205 protein can self-assemble into virus-like particles (VLP) when overexpressed, and can carry antigen fragments, which is beneficial to the uptake and cross-presentation of antigen-presenting cells. In the experiment, geap36 is selected as the coupled antigen, and an experimental group and a control group are established, so as to evaluate whether the VLP vaccine formula can improve the immunogenicity of geap36 and reduce the transmission activity (TRA), and provide a reference for subsequent vaccine research.

The present invention relates to a component for a malaria vaccine comprising: a) an immunogenic particle RTS,S and / or b) an immunogenic particle derived from the CS protein of one or more P. vivax strains and S antigen from Hepatitis B and optionally unfused S antigen, or c) an immunogenic particle comprising RTS, CSV-S and optionally unfused S antigen, and d) a stabilizing agent comprising a stabilizing agent with at least one thiol functional group, or mixtures thereof. Methods for preparing the component, its use in medicine, particularly in the prevention of malarial infections, compositions / vaccines containing the component and use of the latter, particularly in therapy are also disclosed.